LONDON, UK - 5 November 2007 -- SkyePharma PLC (LSE: SKP) today announces that Sciele Pharma Inc.'s (NASDAQ: SCRX) new Sular formulation, which was filed as a supplemental New Drug Application (sNDA) on 30 June 2007 with the U.S. Food & Drug Administration (FDA), has had its Pharmacy Drug User Fee Act (PDUFA) date extended to 2 January 2008 (from 2 November 2007). Sular(R) is a calcium channel blocking agent for the treatment of high blood pressure. The new Sular formulation utilizes SkyePharma’s patented GeomatrixTM technology, which is designed to provide a lower dose of Sular for each of its current doses.
